Regional healthy brain activity, glioma occurrence and symptomatology.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
21 10 2022
Historique:
received: 28 01 2022
revised: 22 04 2022
accepted: 04 05 2022
pubmed: 22 9 2022
medline: 26 10 2022
entrez: 21 9 2022
Statut: ppublish

Résumé

It is unclear why exactly gliomas show preferential occurrence in certain brain areas. Increased spiking activity around gliomas leads to faster tumour growth in animal models, while higher non-invasively measured brain activity is related to shorter survival in patients. However, it is unknown how regional intrinsic brain activity, as measured in healthy controls, relates to glioma occurrence. We first investigated whether gliomas occur more frequently in regions with intrinsically higher brain activity. Second, we explored whether intrinsic cortical activity at individual patients' tumour locations relates to tumour and patient characteristics. Across three cross-sectional cohorts, 413 patients were included. Individual tumour masks were created. Intrinsic regional brain activity was assessed through resting-state magnetoencephalography acquired in healthy controls and source-localized to 210 cortical brain regions. Brain activity was operationalized as: (i) broadband power; and (ii) offset of the aperiodic component of the power spectrum, which both reflect neuronal spiking of the underlying neuronal population. We additionally assessed (iii) the slope of the aperiodic component of the power spectrum, which is thought to reflect the neuronal excitation/inhibition ratio. First, correlation coefficients were calculated between group-level regional glioma occurrence, as obtained by concatenating tumour masks across patients, and group-averaged regional intrinsic brain activity. Second, intrinsic brain activity at specific tumour locations was calculated by overlaying patients' individual tumour masks with regional intrinsic brain activity of the controls and was associated with tumour and patient characteristics. As proposed, glioma preferentially occurred in brain regions characterized by higher intrinsic brain activity in controls as reflected by higher offset. Second, intrinsic brain activity at patients' individual tumour locations differed according to glioma subtype and performance status: the most malignant isocitrate dehydrogenase-wild-type glioblastoma patients had the lowest excitation/inhibition ratio at their individual tumour locations as compared to isocitrate dehydrogenase-mutant, 1p/19q-codeleted glioma patients, while a lower excitation/inhibition ratio related to poorer Karnofsky Performance Status, particularly in codeleted glioma patients. In conclusion, gliomas more frequently occur in cortical brain regions with intrinsically higher activity levels, suggesting that more active regions are more vulnerable to glioma development. Moreover, indices of healthy, intrinsic excitation/inhibition ratio at patients' individual tumour locations may capture both tumour biology and patients' performance status. These findings contribute to our understanding of the complex and bidirectional relationship between normal brain functioning and glioma growth, which is at the core of the relatively new field of 'cancer neuroscience'.

Identifiants

pubmed: 36130310
pii: 6709376
doi: 10.1093/brain/awac180
pmc: PMC9586543
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3654-3665

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Neuron. 2009 Apr 16;62(1):42-52
pubmed: 19376066
Neuroimage. 2018 Sep;178:540-551
pubmed: 29860082
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3867-72
pubmed: 27001844
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Cell. 2015 May 7;161(4):704-6
pubmed: 25957677
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cell. 2015 May 7;161(4):803-16
pubmed: 25913192
Neuro Oncol. 2017 Oct 01;19(10):1316-1326
pubmed: 28419303
Neuro Oncol. 2016 Apr;18(4):479-85
pubmed: 26995789
Neuroimage Clin. 2017 Jan 16;14:87-96
pubmed: 28154795
Hum Brain Mapp. 2013 Jan;34(1):52-61
pubmed: 21954106
Neuro Oncol. 2007 Jul;9(3):319-25
pubmed: 17522333
Neurosurgery. 2012 Jan;70(1):234-43; discussion 243-4
pubmed: 21593697
Neuroimage. 2012 Feb 15;59(4):3909-21
pubmed: 22122866
Cell. 2020 Apr 16;181(2):219-222
pubmed: 32302564
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1731-6
pubmed: 22307639
Hum Brain Mapp. 2009 May;30(5):1524-34
pubmed: 18661502
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
J Neurosci. 2018 Jan 17;38(3):755-764
pubmed: 29167403
PLoS Comput Biol. 2012;8(8):e1002582
pubmed: 22915996
Brain Behav. 2019 Apr;9(4):e01204
pubmed: 30809977
Brain. 2016 Feb;139(Pt 2):547-62
pubmed: 26586695
Ann Int Commun Assoc. 2021;45(2):134-153
pubmed: 34541322
Nature. 2019 Sep;573(7775):532-538
pubmed: 31534219
Nat Neurosci. 2020 Dec;23(12):1655-1665
pubmed: 33230329
PLoS One. 2018 Mar 12;13(3):e0193107
pubmed: 29529085
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Neurooncol. 2018 Nov;140(2):403-412
pubmed: 30094719
Cancer. 2004 Jun 15;100(12):2622-6
pubmed: 15197805
Neuroimage. 2002 Jul;16(3 Pt 1):638-50
pubmed: 12169249
Neuron. 2011 Oct 20;72(2):231-43
pubmed: 22017986
Neurosurgery. 2020 Nov 16;87(6):1078-1084
pubmed: 34791466
J Neurosci. 2009 Oct 28;29(43):13613-20
pubmed: 19864573
Brain. 2016 Dec;139(Pt 12):3063-3083
pubmed: 27497487
Brain. 2020 Dec 5;143(11):3294-3307
pubmed: 33278823
J Cogn Neurosci. 2021 Jan;33(1):3-7
pubmed: 33078992
Sci Data. 2017 Sep 05;4:170117
pubmed: 28872634
Brain Connect. 2021 Dec;11(10):865-874
pubmed: 33947274
Neuroimage Clin. 2013 May 13;2:727-34
pubmed: 24179824
Cell Res. 2015 Aug;25(8):891-2
pubmed: 26032268
Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):
pubmed: 34753819
J Neurooncol. 2020 Mar;147(1):49-58
pubmed: 31953611
Hum Brain Mapp. 2009 Apr;30(4):1077-86
pubmed: 18465745
Nature. 2017 Sep 28;549(7673):533-537
pubmed: 28959975
Nat Neurosci. 2020 Aug;23(8):918-926
pubmed: 32561883
Brain. 2014 Aug;137(Pt 8):2382-95
pubmed: 25057133
Sci Rep. 2021 Sep 23;11(1):18990
pubmed: 34556701
Neuroscience. 2011 Feb 23;175:169-77
pubmed: 21130847
Cereb Cortex. 2016 Aug;26(8):3508-26
pubmed: 27230218
JAMA Netw Open. 2021 Jul 1;4(7):e2114509
pubmed: 34213560

Auteurs

Tianne Numan (T)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.

Lucas C Breedt (LC)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.

Bernardo de A P C Maciel (BAPC)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.

Shanna D Kulik (SD)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.

Jolanda Derks (J)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.

Menno M Schoonheim (MM)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.

Martin Klein (M)

Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Department of Medical Psychology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.

Philip C de Witt Hamer (PC)

Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Department of Neurosurgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.

Julie J Miller (JJ)

Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.

Elizabeth R Gerstner (ER)

Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.

Steven M Stufflebeam (SM)

Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA.

Arjan Hillebrand (A)

Department of Clinical Neurophysiology and MEG Center, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.

Cornelis J Stam (CJ)

Department of Clinical Neurophysiology and MEG Center, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.

Jeroen J G Geurts (JJG)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.

Jaap C Reijneveld (JC)

Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Department of Neurology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Department of Neurology, Stichting Epilepsie Instellingen Nederland, Heemstede 2103 SW, The Netherlands.

Linda Douw (L)

Department of Anatomy and Neurosciences, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Cancer Center Amsterdam, Imaging and Biomarkers, Brain Tumor Center Amsterdam, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Systems and Network Neuroscience, Amsterdam 1081 HV, The Netherlands.
Amsterdam Neuroscience, Brain Imaging, Amsterdam 1081 HV, The Netherlands.
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH